Rapid Response: How mission fuels risk-taking, with Illumina CEO Francis deSouza

<p>Facing off with the FTC isn't for the timid. But when your mission and your business model are aligned, the hard decisions – about risk, about investment, about priorities – become clearer. Francis deSouza is CEO of Illumina, the world’s dominant maker of gene sequencing technology. After playing a key role in the creation of Covid vaccines, Illumina is trying to acquire a company with a breakthrough cancer screening test, over the FTC's objections. DeSouza offers a personal reflection on the lessons and reality of grappling with regulators, highlighting levers that can help to accelerate scale. What underscores his entrepreneurial efforts is a passion for Illumina’s mission: improving human health by unlocking the power of the genome.</p><p>Read a transcript of this interview at:&nbsp;<a href="https://mastersofscale.com/" rel="noopener noreferrer" target="_blank">mastersofscale.com</a></p><p>Subscribe to the Masters of Scale weekly newsletter at&nbsp;<a href="http://eepurl.com/dlirtX" rel="noopener noreferrer" target="_blank">http://eepurl.com/dlirtX</a></p><p>See Privacy Policy at <a href="https://art19.com/privacy" rel="noopener noreferrer" target="_blank">https://art19.com/privacy</a> and California Privacy Notice at <a href="https://art19.com/privacy#do-not-sell-my-info" rel="noopener noreferrer" target="_blank">https://art19.com/privacy#do-not-sell-my-info</a>.</p>